Mark Oldakowski - Bionano Genomics Chief Officer
| BNGO Stock | USD 0.24 0.01 4.00% |
Insider
Mark Oldakowski is Chief Officer of Bionano Genomics
| Age | 50 |
| Address | 9540 Towne Centre Drive, San Diego, CA, United States, 92121 |
| Phone | 858 888 7600 |
| Web | https://www.bionano.com |
Mark Oldakowski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Oldakowski against Bionano Genomics stock is an integral part of due diligence when investing in Bionano Genomics. Mark Oldakowski insider activity provides valuable insight into whether Bionano Genomics is net buyers or sellers over its current business cycle. Note, Bionano Genomics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bionano Genomics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Oldakowski over a year ago Acquisition by Mark Oldakowski of 20000 shares of Bionano Genomics subject to Rule 16b-3 | ||
Mark Oldakowski over a year ago Payment of 41496 shares by Mark Oldakowski of Bionano Genomics subject to Rule 16b-3 | ||
Mark Oldakowski over a year ago Acquisition by Mark Oldakowski of 120000 shares of Bionano Genomics subject to Rule 16b-3 |
Bionano Genomics Management Efficiency
The company has return on total asset (ROA) of (0.3264) % which means that it has lost $0.3264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3833) %, meaning that it created substantial loss on money invested by shareholders. Bionano Genomics' management efficiency ratios could be used to measure how well Bionano Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -1.35. In addition to that, Return On Capital Employed is likely to drop to -1.98. At this time, Bionano Genomics' Net Tangible Assets are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 7.8 M, while Total Assets are likely to drop about 142.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric Conley | Envista Holdings Corp | N/A | |
| Juan Arbona | Envista Holdings Corp | N/A | |
| Kimberly MacKay | West Pharmaceutical Services | 58 | |
| Barry Berler | Sharps Technology | 70 | |
| Theresa Ferguson | Predictive Oncology | N/A | |
| Steven MD | Sharps Technology | 62 | |
| Brian Kidd | Stereotaxis | N/A | |
| Curt Bludworth | Envista Holdings Corp | 53 | |
| Fredrik Widman | Intuitive Surgical | N/A | |
| Eyal MD | Microbot Medical | 59 | |
| Wang Xin | Meihua International Medical | 35 | |
| Constance Bienfait | ResMed Inc | N/A | |
| Francesca DeMartino | Becton Dickinson and | N/A | |
| Robert Myers | Predictive Oncology | 67 | |
| Ching leong | Becton Dickinson and | 53 | |
| Robert Segura | West Pharmaceutical Services | N/A | |
| David Stefansky | Nexgel Inc | 53 | |
| Richard Luzzi | West Pharmaceutical Services | 72 | |
| MScEE MBA | GlucoTrack | 70 | |
| Scott MD | STAAR Surgical | 61 | |
| BE MBA | ResMed Inc | 50 | |
Management Performance
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.33 |
Bionano Genomics Leadership Team
Elected by the shareholders, the Bionano Genomics' board of directors comprises two types of representatives: Bionano Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bionano. The board's role is to monitor Bionano Genomics' management team and ensure that shareholders' interests are well served. Bionano Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bionano Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, General Secretary | ||
| Donna Polizio, Global Access | ||
| Klint Rose, Head Development | ||
| Helene Klein, Chief Officer | ||
| Sheila MBA, Vice Marketing | ||
| Christopher Stewart, Chief Officer | ||
| Jonathan Dixon, Global Legal | ||
| Gulsen MBA, Chief Officer | ||
| Cory Kreeck, Global Operations | ||
| Alka FACMG, Chief Officer | ||
| Mark CPA, VP Controller | ||
| MS MBA, Head Sales | ||
| Mark Oldakowski, Chief Officer | ||
| Robert MBA, CEO and President | ||
| Soheil Shams, CIO Emeritus |
Bionano Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bionano Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (2.03) % | ||||
| Current Valuation | 23.79 M | ||||
| Shares Outstanding | 101.99 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 12.81 % | ||||
| Number Of Shares Shorted | 12.11 M | ||||
| Price To Earning | (1.80) X | ||||
| Price To Book | 0.50 X |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.85 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.78 | VCYT | Veracyte | PairCorr |
| 0.72 | VERA | Vera Therapeutics | PairCorr |
| 0.53 | VANI | Vivani Medical | PairCorr |
| 0.48 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.